A Phase 3 Randomized Active-Controlled Open-Label Clinical Study

Recruiting

99 years or below

All

Phase 3

7 participants needed

1 Location

Brief description of study

Section 3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS p42-47 in the attached protocol Section 3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS p42-47 in the attached protocol Section 4 STUDY DESIGN p47-56 in the attached protocol Section 3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS p42-47 in the attached protocol Section 4 STUDY DESIGN p47-56 in the attached protocol

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 Apr 2023. Study ID: 853217

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 3 Randomized Active-Controlled Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy

Brief description of study

Eligibility of study

Find a site

Interested in the study